Viemed Healthcare (VMD) CFO gets new RSU and phantom share grants

Rhea-AI Filing Summary

Viemed Healthcare (VMD) Chief Financial Officer Trae Fitzgerald reported a mix of equity awards vesting, tax withholding, and new grants. On January 17, 2026, 9,590 restricted stock units and 2,397 cash-settled phantom share units vested, each unit economically equal to one common share. To cover taxes from RSU vesting, 3,132 common shares were withheld at $7.33 per share, based on the January 16, 2026 closing price, and 2,397 common shares were delivered back to the company in connection with phantom share settlement. After these transactions, Fitzgerald directly held 89,452 common shares.

On January 19, 2026, Fitzgerald received new equity awards of 46,662 restricted stock units and 11,666 phantom share units, each with a stated value of $0 per unit on grant and scheduled to vest in three equal annual installments beginning on the first anniversary of the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Trae

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/17/2026		M		9,590	A	(1)	92,584	D
Common Shares	01/17/2026		F		3,132(2)	D	$7.33(3)	89,452	D
Common Shares	01/17/2026		M		2,397	A	(4)	91,849	D
Common Shares	01/17/2026		D		2,397	D	$7.33(3)	89,452	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/17/2026		M			9,590	(5)	01/17/2026	Common Shares	9,590	$0	0	D
Phantom Share Units	(4)	01/17/2026		M			2,397	(6)	01/17/2026	Common Shares	2,397	(4)	0	D
Restricted Stock Units	(1)	01/19/2026		A		46,662		(7)	01/19/2029	Common Shares	46,662	$0	46,662	D
Phantom Share Units	(8)	01/19/2026		A		11,666		(9)	01/19/2029	Common Shares	11,666	$0	11,666	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.

3. Per share value is based on the market closing price of the common shares for January 16, 2026.

4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.

5. Restricted Stock Units (RSUs) granted to reporting person on January 17, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date.

6. Represents an award granted on January 17, 2023 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

7. Restricted Stock Units (RSUs) granted to reporting person on January 19, 2026, which vest in three equal annual installments beginning on the first anniversary of the grant date.

8. Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date.

9. Represents an award granted on January 19, 2026 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Viemed Healthcare (VMD) CFO Trae Fitzgerald report in this Form 4?

The filing shows vesting of existing awards, related share withholding and dispositions to cover taxes and cash settlement, and new grants of restricted stock units and phantom share units to the CFO.

How many new restricted stock units did the VMD CFO receive?

On January 19, 2026, the CFO received 46,662 restricted stock units, each representing a contingent right to receive one common share.

How many new phantom share units were granted to the VMD CFO?

On January 19, 2026, the CFO received 11,666 phantom share units, each representing the right to receive the cash value of one common share based on the share price on the vesting date.

What transactions occurred on January 17, 2026 for Viemed Healthcare (VMD) CFO?

On January 17, 2026, 9,590 restricted stock units and 2,397 phantom share units vested. To satisfy tax obligations and cash settlement, 3,132 common shares were withheld at $7.33 per share and 2,397 common shares were delivered back to the company.

How many Viemed Healthcare common shares does the CFO hold after these transactions?

Following the reported transactions, the CFO directly holds 89,452 common shares of Viemed Healthcare.

At what price were Viemed Healthcare shares valued for tax withholding and dispositions?

The $7.33 per share value used for share withholding and dispositions reflects the market closing price of Viemed Healthcare common shares on January 16, 2026.

How do the new Viemed Healthcare RSU and phantom awards vest for the CFO?

The January 19, 2026 grants of 46,662 restricted stock units and 11,666 phantom share units each vest in three equal annual installments beginning on the first anniversary of the grant date.